Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
NCT ID: NCT06355856
Last Updated: 2024-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
196 participants
INTERVENTIONAL
2024-04-30
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
NCT01231607
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
NCT05599243
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
NCT02280603
A Study to Evaluate the Efficacy and Safety of AD-208
NCT04825561
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
NCT06326359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DNN.22.17.036
Apply 1 ml to the bald area of the scalp, twice a day for 180 days.
DNN.22.17.036
Apply twice daily to the affected area and around it.
10573048700
Apply 1 ml to the bald area of the scalp, twice a day for 180 days.
10573048700
Apply twice daily to the affected area and around it.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNN.22.17.036
Apply twice daily to the affected area and around it.
10573048700
Apply twice daily to the affected area and around it.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male participants age 25 or older and 60 age or younger
* Participants who have an intact scalp in the area of product analysis
* Participants with androgenetic alopecia (AGA) with AGA Norwood-Hamilton Scale \> II
* Participants with at least 20% telogen effluvium of evaluated by Tricholab
Exclusion Criteria
* Participants with other causes of hair loss or scalp dermatoses
* Participants who have received hair loss treatment in the last 6 months
* Participants with uncontrolled medical conditions, kidney and liver disease
* Participants with a history of hair transplantation, malignancy, hematologic disorders, thyroid dysfunction, malnutrition, and other dermatologic disorders that contribute to hair loss
25 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ache Laboratorios Farmaceuticos S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACH-PNT-04(01/22)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.